Previous 10 | Next 10 |
Halozyme Therapeutics (HALO) announces that it intends to offer $500M aggregate principal amount of convertible senior notes due 2027.The company also expects to grant a 30-day option to the initial purchasers to purchase up to an additional $75M aggregate principal amount of convertible note...
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 PR Newswire SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in convertin...
Halozyme Therapeutics (HALO): Q4 GAAP EPS of $0.50 misses by $0.05.Revenue of $121.7M (+126.8% Y/Y) beats by $0.95M.2021 Guidance: Revenues: $375-395M representing 40% to 48% growth Y/Y; EPS of $1.40 to $1.55 representing 54%-70% growth Y/Y and Operating Income of $215-$235M, representin...
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results - Reports Fourth Quarter 2020 Revenue of $121.7 million and Earnings Per Share of $0.50 - - Reports Full Year 2020 Revenue of $267.6 million and Earnings Per Share of $0.91 - - Successful Launch of D...
Halozyme has an excellent royalty business that will terminate in 2027. If they plan to acquire another platform, I will feel a lot more bullish. However, their revenues are constantly on the rise. For further details see: Halozyme: Nice Pivot To A Royalty Business
Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call PR Newswire SAN DIEGO , Feb. 10, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quar...
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis - DARZALEX FASPRO® Utilizing ENHANZE® Represents First and Only Approved Treatment...
Halozyme Therapeutics ([[HALO]] -5.7%) expects its FY21 revenue to range between $375-$395M (+40% to +45% Y/Y), shy of market consensus of $401.22M.The company expects a doubling in revenue from royalties, a significant increase in product sales related to API; however, this guidance exc...
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth - 2021 Revenue Guidance of $375 to $395 Million Representing 40%-45% Growth over Expected 2020 Revenue - - 2021 Royalties Projected to Double versus Expected 2020 Royalties - - 2021 EP...
Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 4, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley , president and chief executive offic...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...